BOSTON--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.
